Joby Aviation closes $591 million stock offering with full underwriter option
Investing.com -- Nexalin Technology Inc (NASDAQ:NXL) stock surged 84.4% in premarket trading Wednesday after the company published positive clinical data showing its brain stimulation technology improved cognitive performance in mild Alzheimer’s disease patients.
The company reported that its proprietary 15 milliamp Gen-2 Nexalin Deep Intracranial Frequency Stimulation (DIFS) technology demonstrated significant cognitive improvements in a randomized, sham-controlled trial published in Radiology. Patients receiving the treatment showed statistically significant improvements in Mini-Mental State Examination scores compared to the control group.
Functional MRI scans confirmed enhanced connectivity between the hippocampus and key cortical regions critical to memory and executive function. The study also revealed increased connectivity across broader cognitive networks commonly disrupted in Alzheimer’s disease.
"The results of this study represent a significant milestone for Nexalin’s technology platform," said Mark White, CEO of Nexalin. "The data clearly supports our belief that Nexalin’s non-invasive deep, frequency-specific neurostimulation can meaningfully improve cognitive performance in patients with Alzheimer’s disease."
The company noted that its Gen-2 SYNC 15 mA DIFS device is already approved in China for treating depression and insomnia, and in Brazil and Oman for anxiety, depression, and insomnia. Nexalin aims to expand treatment indications with various international regulatory agencies, including the FDA in the United States.
No adverse events were reported during the treatment period, supporting the safety profile of the technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.